Ovarian Cancer- Secondary Surgery have no benefits

Cytoreduction surgery (secondary surgery) for ovarian cancer patients failed the study, New England Journal of Medicine.

The Gynecologic Oncology Group (GOG)-0213 (NCT00565851) published a study data from ovarian cancer patients trial in the New England Journal of Medicine. The study trial states that secondary surgery (cytoreduction) followed by chemotherapy for ovarian cancer patients shown zero improvements in the survival rate compared to the survival rate of ovarian cancer patients undergone chemotherapy alone.

The Oncology group study trial experiments ovarian cancer patients with secondary surgery followed by chemotherapy resulting in no improvement in the survival rate of patients. The victims who underwent cytoreductive surgery posed a 29% increased risk of death.

Researchers undergoing trial for nearly 48.1 months of study on ovarian cancer patients, the secondary surgery followed by chemotherapy women survived only 50.6 months compared to the ovarian patients whose overall survival rate prolongs for 64.7 months for chemotherapy treatment alone. The worldwide clinical trial included patients with epithelial ovarian, primary peritoneal, or Fallopian-tube cancer.

National Comprehensive Cancer Network (NCCN) suggests six-month free treatment for ovarian cancer women with prior chemotherapy. The study also involved cytoreductive surgery, followed by platinum-based chemotherapy for nearly 485 patients.

Coleman, M.D., professor of Gynecologic Oncology and Reproductive Medicine, states that the progressive clinical trial conducted by the oncology group shows no benefit to patients treated with secondary surgery. He also added that the clinical practice involving secondary surgery had been changed in his clinic following the study result.

Coleman also suggests questioning the quality of secondary surgery recurrent ovarian cancer patients hoping further better trials to maximize treatment results and survival rate of cancer affected women.